Skip to content
DataLookout
Menu

PRECISIONNCT07924722

Local Iloprost Therapy to Promote Bone Healing in High Risk Fractures

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Radiological fracture healing status at Week 18 assessed by CT
Timeframe: From enrollment to week 18 after surgery

Secondary (8)

Radiological assessment of fracture healing at week 18, and 36 post-surgery (RUSH)
Radiological assessment of fracture healing at week 18, and 36 post-surgery (mRUST)
Radiological assessment of fracture healing at week 18, and 36 post-surgery (2D binary)
Improvement of pain at week 6, 18, 36, and 52, assessed by VAS pain scores
Improvement of health-related quality of life at week 6, 18, 36, and 52, assessed by EQ-5D-5L
Show 3 moreShow less
Improvement physical function at week 6, 18, 36, and 52, assessed by SMFA
Return-to-work at week 6, 18, 36, and 52
Incidence, severity, and relationship of AEs, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE (Version Number V6.0))

Arms and interventions

Treatment ArmExperimental

Iloprost

Control ArmPlacebo comparator

Normal saline (0.9% NaCl)

Drugs: Ilomedin

Other: Normal saline placebo